➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Express Scripts
McKesson
Medtronic

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Namilumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Namilumab?

Namilumab is an investigational drug.

There have been 5 clinical trials for Namilumab. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Psoriasis. The leading clinical trial sponsors are Takeda and [disabled in preview].

There are two US patents protecting this investigational drug and eleven international patents.

Recent Clinical Trials for Namilumab
TitleSponsorPhase
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to MethotrexateTakedaPhase 2
Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)TakedaPhase 2
Single-Dose Study of MT203TakedaPhase 1

See all Namilumab clinical trials

Clinical Trial Summary for Namilumab

Top disease conditions for Namilumab
Top clinical trial sponsors for Namilumab

See all Namilumab clinical trials

US Patents for Namilumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Namilumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Namilumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Namilumab

Drugname Country Document Number Estimated Expiration Related US Patent
Namilumab Australia 2014236559 2033-03-14   Start Trial
Namilumab Brazil 112015022936 2033-03-14   Start Trial
Namilumab Canada 2905108 2033-03-14   Start Trial
Namilumab China 105164143 2033-03-14   Start Trial
Namilumab European Patent Office 2970369 2033-03-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Dow
Express Scripts
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.